Diagnostic effect of CRISPR/Cas12 on JAK2 in lung cancer
Diagnostic effect of CRISPR/Cas12 on JAK2 in lung cancer
Amirsoheil Karami,1Safoora Pakizehkar,2,*
1. Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran 2. Cellular and Molecular Endocrine Research Center (CMERC), Research Institute for Endocrine Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Introduction: Lung cancer constitutes the primary cause of cancer-related mortality. This malady encompasses subtypes such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Conventional diagnostic approaches may not be as effective as CRISPR/Cas12 in the diagnosis and modification of mutations. The latter technique is a highly accurate and efficient tool that can enable a more precise diagnosis of this disease. Notably, CRISPR/Cas12 can detect specific genomic sequences with exceptional precision. JAK2 encodes a non-receptor tyrosine kinase that plays a fundamental role in the development of lung cancer by regulating cellular growth and division. This gene undergoes mutation and decreased expression, and its signaling pathway is crucial in the formation of lung cancer.
Methods: By comparing lung biopsy tissue of patients and healthy people, researchers have found that the increased methylation of JAK2 during cancer development can be detected by CRISPR/CAS12a, thereby facilitating an early diagnosis of lung cancer. For instance, a CRISPR/CAS12a-based nucleic acid detection system that integrates PCR amplification with Cas12a-mediated cleavage can detect the V617F (a common mutation in JAK2), and through the fluorescent detection system in PCR, it can produce strong signals and diagnose the mutated DNA.
Results: In one study involving 14 samples (one patient and 13 healthy controls), CRISPR/Cas12a successfully identified the presence of mutated samples.
Conclusion: Recent studies have investigated the effect of JAK2 gene in the treatment of lung cancer, and we hope that CRISPR will gain approval and lead to the development of a definitive treatment for this disease.